Investors Vie to Lead ImmunityBio Securities Suit
An FDA warning about misleading Anktiva promotions has turned investor losses into the central issue in the fight over who will control the case.
Overview
- A federal class action titled Douglas v. ImmunityBio is pending in the Central District of California and alleges executives materially overstated Anktiva’s capabilities.
- The FDA issued a warning letter dated March 13 that became public on March 24, 2026, saying certain TV ads and a January podcast gave a misleading impression that Anktiva can cure or prevent all cancer.
- The FDA disclosure triggered a steep market reaction, with ImmunityBio shares falling sharply on March 24 and earlier company disclosures also linked to sizeable January declines.
- Multiple plaintiff firms are actively recruiting shareholders and investors have until Tuesday, May 26, 2026, to move the court to be appointed lead plaintiff and select counsel for the class.
- Anktiva is approved only for a limited bladder‑cancer use with BCG, a fact plaintiffs say was downplayed in promotions, and the litigation could determine recovery for investors and future scrutiny of the company’s marketing.